The estimated Net Worth of John Peter Gutfreund is at least $233 Tausend dollars as of 23 December 2022. John Gutfreund owns over 75,000 units of Oncocyte stock worth over $232,500 and over the last 2 years John sold OCX stock worth over $0.
John has made over 2 trades of the Oncocyte stock since 2022, according to the Form 4 filled with the SEC. Most recently John bought 75,000 units of OCX stock worth $24,750 on 23 December 2022.
The largest trade John's ever made was buying 75,000 units of Oncocyte stock on 23 December 2022 worth over $24,750. On average, John trades about 25,000 units every 33 days since 2022. As of 23 December 2022 John still owns at least 75,000 units of Oncocyte stock.
You can see the complete history of John Gutfreund stock trades at the bottom of the page.
John's mailing address filed with the SEC is 767 5TH AVENUE, 44TH FLOOR, , NEW YORK, NY, 10153.
Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin... und Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: